skip to main content
Idioma:

PO.5.116 Lupus nephritis response in terms of kidney function, urine sediment and serological activity after belimumab treatment

De La Rubia Navarro, M ; Grau Garcia, E ; Pavez Perales, C ; Leal Rodriguez, S ; Riesco Barcena, C ; Huaylla Quispe, AV ; Ivorra Cortes, JR ; Gonzalez Puig, L ; Negueroles Albuixech, R ; Martinez Cordellat, I ; Najera Herranz, C ; Fragio Gil, J ; Gonzalez Mazario, R ; Canovas Olmos, I ; Vicens Bernabeu, E ; Oller Rodriguez, J ; Mas Sanchez, L ; Muñoz Martinez, P ; Roman Ivorra, JA

Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A90-A90 [Periódico revisado por pares]

London: Lupus Foundation of America

Texto completo disponível

Citações Citado por
  • Título:
    PO.5.116 Lupus nephritis response in terms of kidney function, urine sediment and serological activity after belimumab treatment
  • Autor: De La Rubia Navarro, M ; Grau Garcia, E ; Pavez Perales, C ; Leal Rodriguez, S ; Riesco Barcena, C ; Huaylla Quispe, AV ; Ivorra Cortes, JR ; Gonzalez Puig, L ; Negueroles Albuixech, R ; Martinez Cordellat, I ; Najera Herranz, C ; Fragio Gil, J ; Gonzalez Mazario, R ; Canovas Olmos, I ; Vicens Bernabeu, E ; Oller Rodriguez, J ; Mas Sanchez, L ; Muñoz Martinez, P ; Roman Ivorra, JA
  • Assuntos: Biopsy ; Friday 07 October 2022 from 13:00 to 14:10 ; Immunosuppressive agents ; Lupus ; Monoclonal antibodies ; Patients ; Sediments ; Serology ; Urine
  • É parte de: Lupus science & medicine, 2022-10, Vol.9 (Suppl 2), p.A90-A90
  • Notas: 13th European Lupus Meeting, Stockholm (October 5–8, 2022)
    PO.5 E- poster session 5: lupus nephritis
  • Descrição: BackgroundSystemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease characterized by an immune dysregulation and autoantibodies production. Kidney affection appears in around 40% of patients and eventually condition the prognosis, morbidity and mortality. Lupus nephritis (LN) is classified into 6 types, being the worst prognosis types III and IV.Belimumab is a monoclonal antibody targeting BLyS approved for SLE, but currently it had no lupus nephritis (NL) indication. In 2020, promising results from a controlled Belimumab trial in LN were published.ObjectiveTo analyze effectiveness of subcutaneous or intravenous Belimumab in LN patients under follow-up by the rheumatology department of a tertiary hospital.MethodsObservational, retrospective, and cross-sectional study including SLE patients according to SLICC/ACR 2012 criteria treated with Belimumab subcutaneous or intravenous. Patients had kidney affection based on pathological findings (kidney biopsy) or urine sediment alterations. A clinical history review was made and serological data, kidney function and urine sediment were collected.ResultsFrom a total of 29 patients treated with belimumab, 9 presented kidney affection. In this group, 8 patients had lupus nephritis demonstrated by kidney biopsy and one patient had an active urine sediment. For them, median age was 37.56 (7.03) years, with 15.13 (8.71) years since SLE diagnosis was made and 4.61 (2.64) years since onset of belimumab. Regarding to type of nephritis, most prevalent type was III (33.3%), followed by type IV (22.22%). Two patients presented combination of both types III and IV and only one patient had type V.The results obtained were included in the table.Abstract PO.5.116 Table 1ConclusionsIn clinical practice, belimumab can improve LN in terms of serological activity, kidney function and urine sediment. It could be a promising option associated to standard therapy for SLE patients with kidney affection. As a future aim, we propose to homogenize therapeutic efficacy definition in order to compare studies and to obtain common conclusions.
  • Editor: London: Lupus Foundation of America
  • Idioma: Inglês
Voltar para lista de resultados

  • Realização: ABCD-USP USP   Logos de Redes Sociais: Freepik

Buscando em bases de dados remotas. Favor aguardar.